MRP-L27 Inhibitors

MRP-L27 inhibitors like cycloheximide and anisomycin are known to inhibit the translocation and peptidyl transferase activity, respectively, of eukaryotic ribosomes and may exhibit similar actions within mitochondria. Antibiotics such as chloramphenicol, tetracycline, erythromycin, azithromycin, and linezolid, developed to target bacterial ribosomes, can interact with mitochondrial ribosomes due to their bacterial evolutionary origin. These can inhibit protein synthesis by binding to the ribosomal subunit, interfering with aminoacyl-tRNA positioning, or preventing peptide elongation. Other compounds like dactinomycin and puromycin affect nucleic acid function and peptide chain elongation, respectively, with potential impacts on mitochondrial ribosomal activity. Dactinomycin binds to DNA and inhibits RNA synthesis, which can extend to mitochondrial DNA, indirectly affecting mitochondrial protein synthesis. Puromycin causes premature chain termination by acting as an analog of aminoacyl-tRNA, which could also occur in mitochondrial ribosomes. Fusidic acid and oligomycin represent another class of inhibitors. Fusidic acid affects protein synthesis by inhibiting the elongation factor G, a critical factor for ribosomal translocation, which could similarly influence mitochondrial translation. Oligomycin inhibits the mitochondrial ATP synthase, thereby reducing the energy supply necessary for all energy-dependent processes within the mitochondria, including protein synthesis. Ricin, although primarily a toxin that targets eukaryotic ribosomes, may have a detrimental effect on mitochondrial ribosomes due to its action on ribosomal RNA.